Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.

Cell reports - 10 May 2016

Jiménez-Valerio Gabriela, Martínez-Lozano Mar, Bassani Nicklas, Vidal August, Ochoa-de-Olza María, Suárez Cristina, García-Del-Muro Xavier, Carles Joan, Viñals Francesc, Graupera Mariona, Indraccolo Stefano, Casanovas Oriol

Abstract excerpt

Antiangiogenic drugs are used clinically for treatment of renal cell carcinoma (RCC) as a standard first-line treatment. Nevertheless, these agents primarily serve to stabilize disease, and resistance eventually develops concomitant with progression. Here, we implicate metabolic symbiosis between tumor cells distal and proximal to remaining vessels as a mechanism of resistance to antiangiogenic therapies in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Everolimus

Share to Indoles

Share to Pyrroles

Share to Sunitinib

Share to TOR Serine-Threonine Kinases

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 27134180
DOI: 10.1016/j.celrep.2016.04.015
PMCID: PMC4870515

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.PMID 27134180Read ↗

A renal cell carcinoma tumorgraft platform to advance precision medicineSemantic proximity Read ↗

The Heterogeneity Metabolism of Renal Cell Carcinomas.Semantic proximity Read ↗

Anaplerotic nutrient stress drives synergy of angiogenesis inhibitors with therapeutics targeting tumor metabolismSemantic proximity Read ↗

The prospect of precision therapy for renal cell carcinoma.Semantic proximity Read ↗

Intratumor Heterogeneity in Primary Kidney Cancer Revealed by Metabolic Profiling of Multiple Spatially Separated Samples within TumorsSemantic proximity Read ↗

Oncometabolite L‐2‐hydroxyglurate directly induces vasculogenic mimicry through PHLDB2 in renal cell carcinomaSemantic proximity Read ↗

Mitochondrial complex I promotes kidney cancer metastasisSemantic proximity Read ↗

Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cellsSemantic proximity Read ↗

Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancersSemantic proximity Read ↗

Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinomaSemantic proximity Read ↗

Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases.Semantic proximity Read ↗

Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.